Dynamic Medical Technologies (4138) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Dynamic Medical Technologies TWD 65.01, price TWD 56.30, upside +15.5%, quality 56 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Dynamic Medical Technologies for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 43.74 TWD – 150.00 TWD · fair‑value band 53.41 TWD – 76.52 TWD · the 56.30 TWD price screens below the 65.01 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Dynamic Medical Technologies in your weekly email
Every Wednesday you see whether Dynamic Medical Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dynamic Medical Technologies Inc., together with its subsidiaries, engages in the sale, maintenance, and marketing of aesthetic lasers and light-based equipment in Taiwan and Hong Kong. It distributes and sells aesthetic medical devices, body contouring devices, dermal fillers, and cosmeceuticals.
Show more
Dynamic Medical Technologies Inc., together with its subsidiaries, engages in the sale, maintenance, and marketing of aesthetic lasers and light-based equipment in Taiwan and Hong Kong. It distributes and sells aesthetic medical devices, body contouring devices, dermal fillers, and cosmeceuticals. The company also provides aesthetician training and clinical operation consultation services. In addition, it sells beauty treatment and cosmetic products. The company was founded in 1992 and is headquartered in New Taipei City, Taiwan.
Stock analysis
Dynamic Medical Technologies (4138) currently trades at 56.30 TWD, while our model-based Fair Value estimate is 65.01 TWD, implying the stock looks roughly 13.4% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 80.80 TWD per share, and 17 of the 24 models we run sit above the 56.30 TWD price.
Bear case: the Asset-Based group reads lowest at 28.00 TWD, and 7 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 53.41 TWD (bear) to 76.52 TWD (bull), the price of 56.30 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Dynamic Medical Technologies reported revenue of 1.4B TWD in FY2025 versus 1.0B TWD in FY2021, a compound +7.8%/yr. Reported net income was 152M TWD in FY2025, compounding +5.4%/yr from FY2021.
Key figures
Market cap 2.2B TWD (≈ $70.8M) · P/E ratio 14.9 · P/S ratio 1.63 · EPS (TTM) 3.79 TWD · Dividend yield 7.5% · Net margin 11.0% · Return on equity 9.7% · Return on assets (EBIT) 7.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 20% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 15%, 4138 screens cheaper than that median.
Fair Value models
Bear 53.41 TWDFair Value 65.01 TWDBull 76.52 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−11.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.5%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.7%
Dividend (yield on the price)7.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.2% vs 2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 13%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−23.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −24.3% a year for the price.
Compare Dynamic Medical Technologies with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 12/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+16% · Top 25%
Profitability
Return on equity (TTM)10% · Above median
Return on assets4% · Above median
Net margin (TTM)10% · Above median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth−2% · Below median
Dividend yield (TTM)7.5% · Top 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dynamic Medical Technologies Fair Value". https://www.fairvalue-calculator.com/stock/4138
Frequently asked questions
Is Dynamic Medical Technologies (4138) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 65.01 TWD versus a price of 56.30 TWD, about +15% upside (undervalued).
What is the fair value of 4138?
Our model-based fair value for Dynamic Medical Technologies is 65.01 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 56.30 TWD.
What is the quality score of 4138?
Dynamic Medical Technologies has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dynamic Medical Technologies (4138)?
Our model-based price target is the fair value of 65.01 TWD (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 53.41 TWD, optimistic scenario 76.52 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Dynamic Medical Technologies stock forecast for 2026?
Our models put fair value at 65.01 TWD, about +15% upside versus a price of 56.30 TWD (undervalued). Cautious scenario 53.41 TWD, optimistic scenario 76.52 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Dynamic Medical Technologies (4138)?
Dynamic Medical Technologies reported trailing-twelve-month revenue of about 1.4B TWD (latest available figure, as of Sep 24, 2026).
Does Dynamic Medical Technologies pay a dividend?
Dynamic Medical Technologies currently shows a dividend yield of about 7.46% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Dynamic Medical Technologies (4138)?
For today's price to be fair in a discounted-cash-flow model, Dynamic Medical Technologies would have to grow free cash flow by -23.1 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4138 use?
Our models discount Dynamic Medical Technologies at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dynamic Medical Technologies that is -23.1 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Dynamic Medical Technologies (4138) delivered so far?
Over the past 5 years revenue at Dynamic Medical Technologies grew +6.6 % a year. The price currently implies -23.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dynamic Medical Technologies (4138) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Dynamic Medical Technologies (-23.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dynamic Medical Technologies (4138)?
The free-cash-flow yield on the price is 11.69 %: that much free cash flow Dynamic Medical Technologies produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dynamic Medical Technologies (4138)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dynamic Medical Technologies it is 65.01 TWD per share (as of Sep 24, 2026), against a price of 56.30 TWD. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Dynamic Medical Technologies stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4138 trades below its calculated fair value: price 56.30 TWD, fair value 65.01 TWD, a gap of about +15% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4138?
No. The price is what the market pays today (56.30 TWD); the fair value is what the company's own numbers justify (65.01 TWD). For Dynamic Medical Technologies the two are 8.71 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Dynamic Medical Technologies worth?
The market values Dynamic Medical Technologies at about 2.2B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 56.30 TWD; our models calculate a fair value of 65.01 TWD per share.
What do the bullish and bearish scenarios say about 4138?
Our models span a range for Dynamic Medical Technologies: cautious scenario 53.41 TWD, base 65.01 TWD, optimistic 76.52 TWD per share (as of Sep 24, 2026, price 56.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4138?
Dynamic Medical Technologies trades at a price-to-earnings ratio of 14.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 65.01 TWD is built from several models across several years. Other multiples: P/B 1.3, P/S 1.6, EV/EBITDA 5.5.
How solid is the balance sheet of Dynamic Medical Technologies (4138)?
Balance-sheet figures for Dynamic Medical Technologies (as of Sep 24, 2026): return on equity 9.7%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 4138 from its 52-week high?
Dynamic Medical Technologies trades at 56.30 TWD, about 20% below its 52-week high of 70.00 TWD and 11% above the low of 50.60 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 65.01 TWD is for.
Which stocks are comparable to Dynamic Medical Technologies?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dynamic Medical Technologies stock attractive at the current price?
The data as of Sep 24, 2026: price 56.30 TWD, calculated fair value 65.01 TWD (+15%), Quality Score 56/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4138 calculated?
We run Dynamic Medical Technologies through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 65.01 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Dynamic Medical Technologies currently trades 15 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dynamic Medical Technologies (4138)?
The closing price on Sep 24, 2026 was 56.30 TWD. Our model-based fair value is 65.01 TWD, about +15% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dynamic Medical Technologies right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Dynamic Medical Technologies
How large is the market capitalisation of Dynamic Medical Technologies (4138)?
The market capitalisation of Dynamic Medical Technologies is 2.2B TWD (≈ $70.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dynamic Medical Technologies (4138)?
The price-to-sales ratio of Dynamic Medical Technologies is 1.63 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dynamic Medical Technologies (4138)?
Earnings per share at Dynamic Medical Technologies are 3.79 TWD (price ÷ EPS = P/E 14.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dynamic Medical Technologies (4138)?
The dividend yield of Dynamic Medical Technologies is 7.5% (payout 111%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dynamic Medical Technologies (4138)?
The net margin of Dynamic Medical Technologies is 11.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dynamic Medical Technologies (4138)?
The return on equity (ROE) of Dynamic Medical Technologies is 9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dynamic Medical Technologies (4138)?
On an EBIT basis the return on assets of Dynamic Medical Technologies is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dynamic Medical Technologies (4138)?
The operating margin of Dynamic Medical Technologies is 10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dynamic Medical Technologies (4138)?
Revenue at Dynamic Medical Technologies is growing −2.4% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dynamic Medical Technologies (4138)?
Earnings per share at Dynamic Medical Technologies are growing −20.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Dynamic Medical Technologies (4138) hold?
Dynamic Medical Technologies holds more cash than debt, 483M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Dynamic Medical Technologies in the live analysis
One click puts Dynamic Medical Technologies on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
